<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Foot Ankle Int</journal-id><journal-id journal-id-type="iso-abbrev">Foot Ankle Int</journal-id><journal-id journal-id-type="pmc-domain-id">464</journal-id><journal-id journal-id-type="pmc-domain">sageopen</journal-id><journal-id journal-id-type="publisher-id">FAI</journal-id><journal-title-group><journal-title>Foot &amp; Ankle International</journal-title></journal-title-group><issn pub-type="ppub">1071-1007</issn><issn pub-type="epub">1944-7876</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Sage Choice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12145462</article-id><article-id pub-id-type="pmcid-ver">PMC12145462.1</article-id><article-id pub-id-type="pmcaid">12145462</article-id><article-id pub-id-type="pmcaiid">12145462</article-id><article-id pub-id-type="pmid">40162958</article-id><article-id pub-id-type="doi">10.1177/10711007251328370</article-id><article-id pub-id-type="publisher-id">10.1177_10711007251328370</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>GLP-1 Agonists&#8217; Effect on Infection and Union after Tibiotalar Fusion, Subtalar Fusion, Triple Arthrodesis</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1591-8466</contrib-id><name name-style="western"><surname>Levidy</surname><given-names initials="MF">Michael F.</given-names></name><degrees>MD</degrees><xref rid="aff1-10711007251328370" ref-type="aff">1</xref><xref rid="corresp1-10711007251328370" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vatsia</surname><given-names initials="S">Sohrab</given-names></name><degrees>MD</degrees><xref rid="aff1-10711007251328370" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tucker</surname><given-names initials="S">Scott</given-names></name><degrees>MD</degrees><xref rid="aff1-10711007251328370" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rowe</surname><given-names initials="N">Nicholas</given-names></name><degrees>MD</degrees><xref rid="aff1-10711007251328370" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Macdonald</surname><given-names initials="A">Ashlee</given-names></name><degrees>MD</degrees><xref rid="aff1-10711007251328370" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2944-4927</contrib-id><name name-style="western"><surname>Aynardi</surname><given-names initials="M">Michael</given-names></name><degrees>MD</degrees><xref rid="aff1-10711007251328370" ref-type="aff">1</xref></contrib></contrib-group><aff id="aff1-10711007251328370"><label>1</label>Department of Orthopaedics &amp; Rehabilitation, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA</aff><author-notes><corresp id="corresp1-10711007251328370">Michael F. Levidy, MD, Department of Orthopaedics &amp; Rehabilitation, Penn State Milton S. Hershey Medical Center, 500 University Drive, Hershey, PA 17033-2360, USA. Email: <email>mlevidy@pennstatehealth.psu.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2025</year></pub-date><volume>46</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">490144</issue-id><fpage>617</fpage><lpage>621</lpage><pub-history><event event-type="pmc-release"><date><day>08</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-09 00:25:29.133"><day>09</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder content-type="sage">American Orthopaedic Foot &amp; Ankle Society</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution 4.0 License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_10711007251328370.pdf"/><abstract><sec id="section1-10711007251328370"><title>Background:</title><p>GLP-1 agonist use has increased due to the rising prevalence of obesity and diabetes mellitus. Foot and ankle surgeons provide orthopaedic care to diabetic patients. The effects of GLP-1 agonists on foot fusion outcomes are not well explored.</p></sec><sec id="section2-10711007251328370"><title>Methods:</title><p>The TriNetX Global Collaborative Network was queried using <italic toggle="yes">CPT</italic> codes for patients with diabetes mellitus undergoing open tibiotalar fusions, subtalar fusions, and triple arthrodesis. Outcomes were assessed at 1&#8201;year after index surgical procedure. Cohort balancing was performed according to age at procedure, race, sex, and nicotine dependence, for body mass index, glycated hemoglobin (HbA<sub>1c</sub>), and estimated glomerular filtration rate (eGFR). Statistical significance was set at <italic toggle="yes">P</italic>&#8201;&lt;.05 with associated 95% CIs.</p></sec><sec id="section3-10711007251328370"><title>Results:</title><p>Two cohorts of 783 patients undergoing tibiotalar, subtalar, or triple arthrodesis fusions were compared using <italic toggle="yes">CPT</italic> coding in this study (Table 1). Among patients treated with GLP-1 agonists, the overall rate of postoperative pseudarthrosis was found to be lower (15.9% vs 20.2%, <italic toggle="yes">P</italic>&#8201;=&#8201;.0129, RR 1.26 (1.02-1.56). Comparison of constituent procedures in isolation showed a lower rate of pseudarthrosis for patients using GLP-1 agonist than matched controls: subtalar fusion (17.2% vs 23.4%, <italic toggle="yes">P</italic>&#8201;=&#8201;.0292, RR 1.36, 95% CI 1.03-1.79) and triple arthrodesis (12.4% vs 21.9%, <italic toggle="yes">P</italic>&#8201;=&#8201;.0120, RR 1.76, 95% CI 1.12-2.76). No significant difference was found in rates of pseudarthrosis after tibiotalar fusion (19.8% vs 21.5%, <italic toggle="yes">P</italic>&#8201;=&#8201;.5692, RR 1.09, 95% CI 0.81-1.46). No difference was detected in postoperative infection rates for any of the procedure types (Table 3).</p></sec><sec id="section4-10711007251328370"><title>Conclusion:</title><p>Results suggest a previously unreported better fusion rates associated with GLP-1 agonist use after fusion procedures of the foot and ankle. This study also shows no clear risk or benefit associated with GLP-1 agonists with respect to postoperative infection. Additional clinical studies are needed to clarify this association.</p></sec></abstract><kwd-group><kwd>fusion</kwd><kwd>diabetes</kwd><kwd>GLP-1 agonists</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p><bold>Level of Evidence:</bold> Level III, database cohort study.</p><sec sec-type="intro" id="section5-10711007251328370"><title>Introduction</title><p>Glucagon-like peptide 1 (GLP-1) receptor agonists are commonly used to treat diabetes and obesity and to decrease the risk of heart attack and stroke.<sup>
<xref rid="bibr14-10711007251328370" ref-type="bibr">14</xref>
</sup> These medications work through &#8220;augmentation of hyperglycemia-induced insulin secretion and suppression of glucagon secretion at hyper- or euglycemia.&#8221;<sup>
<xref rid="bibr10-10711007251328370" ref-type="bibr">10</xref>
</sup> Drugs within the class have the same underlying mechanism of action, however, various GLP-1 receptor agonists have varying formulations and methods of administration.<sup>
<xref rid="bibr4-10711007251328370" ref-type="bibr">4</xref>
</sup> Use of drugs in this category has skyrocketed, with prescriptions of semaglutide in the United States climbing to more than 8 000&#8201;000 at the end of 2022, with a greater than 300% increase in prescription volume demonstrated between Q1 2020 and Q4 2022.<sup>
<xref rid="bibr16-10711007251328370" ref-type="bibr">16</xref>
</sup></p><p>Despite the success and increasing popularity of these medications, there are important side effects that can affect patients perioperatively. The American Society of Anesthesiologists has issued consensus-based guidelines, which include pausing GLP-1 receptor agonists before surgery out of concern for regurgitation and aspiration in the setting of delayed gastric emptying.<sup>
<xref rid="bibr8-10711007251328370" ref-type="bibr">8</xref>
</sup> These medications may also play a role in bone quality: clinical trial data have demonstrated that patients taking semaglutide have a 5 times increased risk of hip and pelvic fractures in female patients and 4 times increased risk in patients older than 75&#8201;years of age (1.0% [24/2448] vs 0.2% [5/2424], 2.4% [17/703] vs 0.6% [4/663], respectively).<sup>
<xref rid="bibr5-10711007251328370" ref-type="bibr">5</xref>
</sup></p><p>Tibiotalar joint degeneration can result in significant pain and functional limitations. First described by Albert in 1879, ankle arthrodesis has emerged as a reliable way to achieve good clinical outcomes with widely reported rates of successful union and infection.<sup>
<xref rid="bibr18-10711007251328370" ref-type="bibr">18</xref>
</sup> Similarly, subtalar arthritis can be responsible for significant pain and functional limitation, with subtalar arthrodesis providing reliable improvements in pain and function. It is understood that poor glucose control increases risk of infection and nonunion in the setting of ankle and/or hindfoot arthrodesis. Therefore, in the setting of increasing use of GLP-1 receptor agonists, and the lack of literature examining the potential impact on orthopaedic procedures, we examine rates of infection and nonunion in patients treated with GLP-1 agonist therapy.</p></sec><sec sec-type="methods" id="section6-10711007251328370"><title>Methods</title><p>The TriNetX Databse was chosen for its wide inclusion of more than 100 Healthcare Organizations (HCOs) encompassing main and satellite locations, academic and nonacademic settings, and pharmacy data. Data are prospectively collected and deidentified by the HCO via their Electronic Medical Record and shared with TriNetX. TriNetX was queried for patients with an underlying diagnosis of type 2 diabetes mellitus who underwent tibiotalar fusion, subtalar fusion, and triple arthrodesis from 2005 to 2024. Arthroscopic procedure codes were excluded to limit experimental variables and reduce confounding. Pantalar fusions were excluded due to a much smaller sample size (n&#8201;&lt;&#8201;100) relative to the included procedures. <italic toggle="yes">Current Procedural Terminology</italic> (<italic toggle="yes">CPT</italic>) coding was used to query procedure types (<xref rid="table1-10711007251328370" ref-type="table">Table 1</xref>). <italic toggle="yes">International Classification of Diseases</italic> (<italic toggle="yes">ICD</italic>) coding was not used because it lacks unique codes to distinguish Subtalar Fusion and Triple Arthrodesis in the TriNetX system. Patients were split into cohorts based on whether they had been prescribed or represcribed GLP1-agonist medications up to 1&#8201;year before surgery. Medication data was queried using TriNetX medication data codes for the following medications: tirzepatide, semaglutide, lixisenatide, dulaglutide, liraglutide, and pramlintide.</p><table-wrap position="float" id="table1-10711007251328370" orientation="portrait"><label>Table 1.</label><caption><p><italic toggle="yes">CPT</italic> Codes Queried and Their Corresponding Procedures.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_10711007251328370-table1.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Procedure</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">CPT</italic>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Tibiotalar fusions</td><td rowspan="1" colspan="1">27870</td></tr><tr><td rowspan="1" colspan="1">Subtalar fusion</td><td rowspan="1" colspan="1">28725</td></tr><tr><td rowspan="1" colspan="1">Triple arthrodesis</td><td rowspan="1" colspan="1">28715</td></tr></tbody></table></alternatives></table-wrap><p>Cohorts were propensity-matched 1:1 according to a greedy-nearest-neighbor matching algorithm with a caliper of 0.1 pooled SDs. Categorical variables included in the model were age at procedure, race, sex, and nicotine dependence. Body mass index (BMI), glycated hemoglobin (HbA<sub>1c</sub>), and estimated glomerular filtration rate were used to balance the cohort for severity of diabetes. Cohorts were balanced for these variables based on the categorizations in <xref rid="table2-10711007251328370" ref-type="table">Table 2</xref>. Outcomes of interest in this study were evaluated at 1&#8201;year and included failure to achieve fusion and postsurgical infection. Failure to achieve fusion was defined as those patients receiving a new diagnosis of <italic toggle="yes">ICD-10</italic> code M96.0, pseudarthrosis after fusion, or arthrodesis. Postsurgical infection was defined as those patients with a new diagnosis of <italic toggle="yes">ICD-10</italic> code T81.4, infection following a procedure.</p><table-wrap position="float" id="table2-10711007251328370" orientation="portrait"><label>Table 2.</label><caption><p>Groupings of Continuous Variables for Cohort Matching.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_10711007251328370-table2.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">BMI</th><th align="center" rowspan="1" colspan="1">HbA<sub>1c</sub></th><th align="center" rowspan="1" colspan="1">eGFR</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">0-20</td><td rowspan="1" colspan="1">0-5.6</td><td rowspan="1" colspan="1">0-15</td></tr><tr><td rowspan="1" colspan="1">21-25</td><td rowspan="1" colspan="1">5.6-6.5</td><td rowspan="1" colspan="1">15-30</td></tr><tr><td rowspan="1" colspan="1">26-30</td><td rowspan="1" colspan="1">6.6-7.5</td><td rowspan="1" colspan="1">30-45</td></tr><tr><td rowspan="1" colspan="1">31-35</td><td rowspan="1" colspan="1">7.6-8.5</td><td rowspan="1" colspan="1">45-60</td></tr><tr><td rowspan="1" colspan="1">36-40</td><td rowspan="1" colspan="1">8.6-9.5</td><td rowspan="1" colspan="1">60-90</td></tr><tr><td rowspan="1" colspan="1">40+</td><td rowspan="1" colspan="1">9.5+</td><td rowspan="1" colspan="1">90+</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-10711007251328370"><p>Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA<sub>1c</sub>, glycated hemoglobin.</p></fn></table-wrap-foot></table-wrap><p>The percentages of patients from each cohort who developed these outcomes were compared for each procedure type. Subsequently, a combined analysis was performed analyzing outcomes after any of the 3 procedures (tibiotalar fusion, subtalar fusion, and triple arthrodesis). The TriNetX platform software was used to run &#967;<sup>2</sup> tests for statistical significance. Statistical significance was set at <italic toggle="yes">P</italic>&#8201;&lt;.05 with associated 95% CIs.</p></sec><sec sec-type="results" id="section7-10711007251328370"><title>Results</title><p>Two cohorts of 783 patients undergoing tibiotalar, subtalar, or triple arthrodeses fusions were compared using <italic toggle="yes">CPT</italic> coding in this study (<xref rid="table1-10711007251328370" ref-type="table">Table 1</xref>). Among patients treated with GLP-1 agonists, the overall rate of postoperative pseudarthrosis was found to be lower (15.9% vs 20.2%, <italic toggle="yes">P</italic>&#8201;=&#8201;.0129; relative risk [RR] 1.26, 95% CI 1.02-1.56). Comparison of constituent procedures in isolation showed a lower rate of pseudarthrosis GLP-1&#8211;receiving patients who underwent subtalar fusion (17.2% vs 23.4%, <italic toggle="yes">P</italic>&#8201;=&#8201;.0292; RR 1.36, 95% CI 1.03-1.79) and triple arthrodesis (12.4% vs 21.9%, <italic toggle="yes">P</italic>&#8201;=&#8201;.0120; RR 1.76, 95% CI 1.12-2.76). No significant difference was found in rates of pseudarthrosis after tibiotalar fusion (19.8% vs 21.5%, <italic toggle="yes">P</italic>&#8201;=&#8201;.5692; RR 1.09, 95% CI 0.81-1.46). No difference was detected in postoperative infection rates for any of the procedure types (<xref rid="table3-10711007251328370" ref-type="table">Table 3</xref>). Additional data on patient demographic breakdown is provided in <xref rid="table4-10711007251328370" ref-type="table">Table 4</xref>.</p><table-wrap position="float" id="table3-10711007251328370" orientation="portrait"><label>Table 3.</label><caption><p>Outcomes After Fusion Procedures Queried Using <italic toggle="yes">CPT</italic> Codes.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_10711007251328370-table3.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"><italic toggle="yes">CPT</italic> Only</th><th align="center" rowspan="1" colspan="1">Cohort Size, n</th><th align="center" rowspan="1" colspan="1">Pseudarthrosis, n (%)</th><th align="center" rowspan="1" colspan="1">Infection, n (%)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Tibiotalar</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Without GLP-1</td><td rowspan="1" colspan="1">339</td><td rowspan="1" colspan="1">73 (21.5)</td><td rowspan="1" colspan="1">43 (12.7)</td></tr><tr><td rowspan="1" colspan="1">&#8195;With GLP-1</td><td rowspan="1" colspan="1">339</td><td rowspan="1" colspan="1">67 (19.8)</td><td rowspan="1" colspan="1">42 (12.4)</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#8195;P</italic>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.5692</td><td rowspan="1" colspan="1">.9077</td></tr><tr><td rowspan="1" colspan="1">&#8195;RR (95% CI)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1.09 (0.81, 1.46)</td><td rowspan="1" colspan="1">1.02 (0.65, 1.62)</td></tr><tr><td rowspan="1" colspan="1">Subtalar</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Without GLP-1</td><td rowspan="1" colspan="1">406</td><td rowspan="1" colspan="1">95 (23.4)</td><td rowspan="1" colspan="1">42 (10.3)</td></tr><tr><td rowspan="1" colspan="1">&#8195;With GLP-1</td><td rowspan="1" colspan="1">406</td><td rowspan="1" colspan="1">70 (17.2)</td><td rowspan="1" colspan="1">50 (12.3)</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#8195;P</italic>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<bold>.0292</bold>
</td><td rowspan="1" colspan="1">.3758</td></tr><tr><td rowspan="1" colspan="1">&#8195;RR (95% CI)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1.36 (1.03, 1.79)</td><td rowspan="1" colspan="1">0.84 (0.57, 1.24)</td></tr><tr><td rowspan="1" colspan="1">Triple</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Without GLP-1</td><td rowspan="1" colspan="1">201</td><td rowspan="1" colspan="1">44 (21.9)</td><td rowspan="1" colspan="1">18 (8.9)</td></tr><tr><td rowspan="1" colspan="1">&#8195;With GLP-1</td><td rowspan="1" colspan="1">201</td><td rowspan="1" colspan="1">25 (12.4)</td><td rowspan="1" colspan="1">16 (7.9)</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#8195;P</italic>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<bold>.0120</bold>
</td><td rowspan="1" colspan="1">.72</td></tr><tr><td rowspan="1" colspan="1">&#8195;RR (95% CI)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1.76 (1.12, 2.76)</td><td rowspan="1" colspan="1">1.13 (0.59, 2.14)</td></tr><tr><td rowspan="1" colspan="1">Tibiotalar or subtalar or triple</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Without GLP-1</td><td rowspan="1" colspan="1">783</td><td rowspan="1" colspan="1">158 (20.2)</td><td rowspan="1" colspan="1">73 (9.3)</td></tr><tr><td rowspan="1" colspan="1">&#8195;With GLP-1</td><td rowspan="1" colspan="1">783</td><td rowspan="1" colspan="1">125 (15.9)</td><td rowspan="1" colspan="1">77 (9.8)</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#8195;P</italic>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<bold>.0129</bold>
</td><td rowspan="1" colspan="1">.73</td></tr><tr><td rowspan="1" colspan="1">&#8195;RR (95% CI)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1.26 (1.02, 1.56)</td><td rowspan="1" colspan="1">0.83 (0.67, 1.32)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn2-10711007251328370"><p>Abbreviations: <italic toggle="yes">CPT</italic>, <italic toggle="yes">Current Procedural Terminology</italic>; GLP-1, glucagon-like peptide 1; RR, relative risk.</p></fn><fn id="table-fn3-10711007251328370"><p>Boldface indicates significance (<italic toggle="yes">P</italic> &lt; .05).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="table4-10711007251328370" orientation="portrait"><label>Table 4.</label><caption><p>Patient Demographics.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_10711007251328370-table4.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1">Without GLP-1</th><th align="center" colspan="4" rowspan="1">With GLP 1</th><th rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="center" rowspan="1" colspan="1">Patient Count</th><th align="center" rowspan="1" colspan="1">Percent</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">SD</th><th align="center" rowspan="1" colspan="1">Patient Count</th><th align="center" rowspan="1" colspan="1">Percent</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">SD</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age at index</td><td rowspan="1" colspan="1">783</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">57.15</td><td rowspan="1" colspan="1">12.05</td><td rowspan="1" colspan="1">783</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">57.74</td><td rowspan="1" colspan="1">9.93</td><td rowspan="1" colspan="1">.29</td></tr><tr><td rowspan="1" colspan="1">White</td><td rowspan="1" colspan="1">568</td><td rowspan="1" colspan="1">72.54</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">566</td><td rowspan="1" colspan="1">72.29</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.91</td></tr><tr><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">379</td><td rowspan="1" colspan="1">48.40</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">371</td><td rowspan="1" colspan="1">47.38</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.69</td></tr><tr><td rowspan="1" colspan="1">Black or African American</td><td rowspan="1" colspan="1">126</td><td rowspan="1" colspan="1">16.09</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">119</td><td rowspan="1" colspan="1">15.20</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.63</td></tr><tr><td rowspan="1" colspan="1">Hispanic or Latino</td><td rowspan="1" colspan="1">78</td><td rowspan="1" colspan="1">9.96</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">76</td><td rowspan="1" colspan="1">9.71</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.87</td></tr><tr><td rowspan="1" colspan="1">Asian</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">1.28</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">1.28</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&gt;.99</td></tr><tr><td colspan="10" rowspan="1">
<bold>Medical comorbidities</bold>
</td></tr><tr><td rowspan="1" colspan="1">&#8195;Chronic ischemic heart disease</td><td rowspan="1" colspan="1">164</td><td rowspan="1" colspan="1">20.95</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">173</td><td rowspan="1" colspan="1">22.10</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.58</td></tr><tr><td rowspan="1" colspan="1">&#8195;Personal history of nicotine dependence</td><td rowspan="1" colspan="1">151</td><td rowspan="1" colspan="1">19.29</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">149</td><td rowspan="1" colspan="1">19.03</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.90</td></tr><tr><td rowspan="1" colspan="1">&#8195;Peripheral vascular disease</td><td rowspan="1" colspan="1">116</td><td rowspan="1" colspan="1">14.82</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">118</td><td rowspan="1" colspan="1">15.07</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.89</td></tr><tr><td rowspan="1" colspan="1">&#8195;Chronic obstructive pulmonary disease</td><td rowspan="1" colspan="1">58</td><td rowspan="1" colspan="1">7.41</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">71</td><td rowspan="1" colspan="1">9.07</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.23</td></tr><tr><td rowspan="1" colspan="1">&#8195;Fibrosis and cirrhosis of liver</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">3.19</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">2.94</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.77</td></tr><tr><td rowspan="1" colspan="1">&#8195;eGFR</td><td rowspan="1" colspan="1">605</td><td rowspan="1" colspan="1">77.27</td><td rowspan="1" colspan="1">69.16</td><td rowspan="1" colspan="1">30.20</td><td rowspan="1" colspan="1">591</td><td rowspan="1" colspan="1">75.48</td><td rowspan="1" colspan="1">70.12</td><td rowspan="1" colspan="1">29.32</td><td rowspan="1" colspan="1">.58</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;0-30</td><td rowspan="1" colspan="1">144</td><td rowspan="1" colspan="1">18.39</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">139</td><td rowspan="1" colspan="1">17.75</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.74</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;30-60</td><td rowspan="1" colspan="1">302</td><td rowspan="1" colspan="1">38.57</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">310</td><td rowspan="1" colspan="1">39.59</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.68</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;60-90</td><td rowspan="1" colspan="1">403</td><td rowspan="1" colspan="1">51.47</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">425</td><td rowspan="1" colspan="1">54.28</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.27</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;At least 90</td><td rowspan="1" colspan="1">258</td><td rowspan="1" colspan="1">32.95</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">271</td><td rowspan="1" colspan="1">34.61</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.49</td></tr><tr><td rowspan="1" colspan="1">&#8195;BMI</td><td rowspan="1" colspan="1">591</td><td rowspan="1" colspan="1">75.48</td><td rowspan="1" colspan="1">37.26</td><td rowspan="1" colspan="1">8.01</td><td rowspan="1" colspan="1">612</td><td rowspan="1" colspan="1">78.16</td><td rowspan="1" colspan="1">37.52</td><td rowspan="1" colspan="1">7.52</td><td rowspan="1" colspan="1">.56</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;0-20</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">2.17</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">2.04</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.86</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;20-30</td><td rowspan="1" colspan="1">152</td><td rowspan="1" colspan="1">19.41</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">164</td><td rowspan="1" colspan="1">20.95</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.45</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;30-40</td><td rowspan="1" colspan="1">370</td><td rowspan="1" colspan="1">47.25</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">397</td><td rowspan="1" colspan="1">50.70</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.17</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;&#8805;40</td><td rowspan="1" colspan="1">294</td><td rowspan="1" colspan="1">37.55</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">305</td><td rowspan="1" colspan="1">38.95</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.57</td></tr><tr><td rowspan="1" colspan="1">&#8195;HbA<sub>1c</sub></td><td rowspan="1" colspan="1">548</td><td rowspan="1" colspan="1">69.99</td><td rowspan="1" colspan="1">7.44</td><td rowspan="1" colspan="1">1.75</td><td rowspan="1" colspan="1">540</td><td rowspan="1" colspan="1">68.97</td><td rowspan="1" colspan="1">7.31</td><td rowspan="1" colspan="1">1.73</td><td rowspan="1" colspan="1">.24</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;0%-5.6%</td><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">5.75</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">61</td><td rowspan="1" colspan="1">7.79</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.11</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;5.6%-6.5%</td><td rowspan="1" colspan="1">221</td><td rowspan="1" colspan="1">28.23</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">241</td><td rowspan="1" colspan="1">30.78</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.27</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;6.5%-7.5%</td><td rowspan="1" colspan="1">291</td><td rowspan="1" colspan="1">37.17</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">301</td><td rowspan="1" colspan="1">38.44</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.60</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;7.5%-8.5%</td><td rowspan="1" colspan="1">262</td><td rowspan="1" colspan="1">33.46</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">252</td><td rowspan="1" colspan="1">32.18</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.59</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;&#8805;8.5%</td><td rowspan="1" colspan="1">274</td><td rowspan="1" colspan="1">34.99</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">277</td><td rowspan="1" colspan="1">35.38</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">.87</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn4-10711007251328370"><p>Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; GLP-1, glucagon-like peptide 1; HbA<sub>1c</sub>, glycated hemoglobin.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion" id="section8-10711007251328370"><title>Discussion</title><p>We used a retrospective database review to evaluate the impact of GLP-1 agonists on rates of infection and nonunion after tibiotalar fusion, subtalar fusion, and triple arthrodesis. Our data showed an increase in rates of union associated with those receiving GLP-1 agonists. Our data demonstrated similar rates of infection and fusion as Cardoso and Veljkovic&#8217;s.<sup>
<xref rid="bibr2-10711007251328370" ref-type="bibr">2</xref>
</sup> Similarly, Wong et al<sup>
<xref rid="bibr17-10711007251328370" ref-type="bibr">17</xref>
</sup> reported nonunion and infection rates of 16% and 6%, respectively. A 2021 systematic literature review by Oshba et al<sup>
<xref rid="bibr12-10711007251328370" ref-type="bibr">12</xref>
</sup> reported similar fusion rates. Overall, our patient demographics indicate a representative sample of orthopaedic patients and their comorbidities, suggesting good generalizability to many practice environments (<xref rid="table4-10711007251328370" ref-type="table">Table 4</xref>).</p><p>Orthopaedic surgeons, particularly those operating about the foot and ankle, are well aware of the impact diabetes and glycemic control can have on postsurgical outcomes. Previous studies have demonstrated increased complication rate and infection rate after hindfoot fusion in patients with poorly controlled diabetes.<sup>
<xref rid="bibr9-10711007251328370" ref-type="bibr">9</xref>
</sup> Similarly, previous work has demonstrated higher rates of complications with ankle fracture management in uncontrolled diabetics as compared to controlled diabetics.<sup>
<xref rid="bibr7-10711007251328370" ref-type="bibr">7</xref>
</sup> GLP-1 agonists have previously been shown to reduce perioperative glucose and insulin administration without the risk for hypoglycemia.<sup>
<xref rid="bibr6-10711007251328370" ref-type="bibr">6</xref>
</sup> Perhaps less well known are the immunologic and anti-inflammatory effects of GLP-1 agonists,<sup>
<xref rid="bibr1-10711007251328370" ref-type="bibr">1</xref>
</sup> which may raise concern for infectious risk. Concurrently, there is a growing body of evidence to suggest that GLP-1 agonists impact bone metabolism. Nuche-Berenguer et al demonstrated increases in bone-anabolic agents such as osteoprotegerin and RANKL, in addition to decreased trabecular anisotropy.<sup>
<xref rid="bibr11-10711007251328370" ref-type="bibr">11</xref>
</sup> Prior work demonstrates that GLP-1 agonist therapy promotes bone formation, downregulates bone resorption, and alters the balance between resorption and formation during remodeling.<sup>
<xref rid="bibr19-10711007251328370" ref-type="bibr">19</xref>
</sup> On a cellular level, an increase in osteoblasts and osteoclasts, but also decreased osteoclast activity, has been shown in mice receiving chronic GLP-1 therapy.<sup>
<xref rid="bibr13-10711007251328370" ref-type="bibr">13</xref>
</sup> These results were re-created more recently by Cheng et al,<sup>
<xref rid="bibr3-10711007251328370" ref-type="bibr">3</xref>
</sup> who found GLP-1 agonist therapy attenuated osteoporosis by preventing deterioration of trabecular microarchitecture and enhancing bone strength in a diabetic mouse model.</p><p>A causative relationship cannot be established based on the outcomes of this study; however, our findings may have a mechanistic underpinning. The aforementioned decrease in osteoclastic activity<sup>
<xref rid="bibr19-10711007251328370" ref-type="bibr">19</xref>
</sup> may leave additional bone at the fusion site. This, combined with enhanced glucose control<sup>
<xref rid="bibr6-10711007251328370" ref-type="bibr">6</xref>
</sup> and upregulated osteoblasts may favor bony fusion, and account for the increased rate of fusion documented in our study. This study found no difference in rates of infection despite the known benefit of GLP-1 agonists on perioperative glucose control. Countervailing phenomena associated with GLP-1 agonists may play a role here - improved glucose control may reduce infectious risk, but other effects of GLP-1 agonists, namely, a previously documented antiinflammatory and possibly immunomodulatory effect,<sup>
<xref rid="bibr1-10711007251328370" ref-type="bibr">1</xref>
</sup> may offset it. Additional research is needed to parse the exact effect these medications make on the immune system and operative infectious risk independent of their effects on glucose control.</p><p>This is a retrospective database study and therefore limited by the accuracy of inputted coding data. Notably, tibiotalar fusions did not significantly differ between GLP-1&#8211;treated and GLP-1-na&#239;ve patients. This may be a result of cross-coding arthroscopic vs open procedures leading to a higher variance in outcomes. The relative popularity of the arthroscopic approach to tibiotalar fusion may have made this procedure particularly vulnerable to confounding. Another limitation of this study is the inability to assess individual patients imaging or functional status for indicators of fusion quality, such as subsequent refracture through the fusion site. Further limitation is introduced by the spectrum of diagnostic parameters that spur providers to enter a database-discoverable pseudarthrosis code&#8212;some may rely on purely clinical factors to assess fusion, while others may prefer evaluation via radiography or CT scan. These limitations are of particular concern for patients taking GLP-1 agonists given the possible attenuation of bone remodeling at the fusion cite via downregulated osteoclast activity. Another limitation is conflicting indications for GLP-1 usage. The data collection period for this study straddles the 2015 FDA approval for a weight loss indication, before this, GLP-1 agonists were only indicated for diabetic control. Different dosages of GLp-1 agonists are used for different indications, and may confound the results. Similarly, duration of GLP-1 therapy may confound results. In this study, we included patients who had been prescribed GLP1 therapy between 1&#8201;week and 1&#8201;year of surgery. Although GLP-1 medications have been shown to impact blood glucose in days to a week,<sup>
<xref rid="bibr15-10711007251328370" ref-type="bibr">15</xref>
</sup> it is possible that effects on bony metabolism take longer to manifest. The role of better glucose control and weight control based on duration of exposure to GLP-1 agonists may also confound outcomes and pose limitations to our findings.</p></sec><sec sec-type="conclusions" id="section9-10711007251328370"><title>Conclusion</title><p>In this propensity-matched database study we found that patients taking GLP-1 agonists were associated with increased rates of fusion after undergoing subtalar, and triple arthrodesis. Analysis of combined procedures similarly showed an increased rate of fusion in GLP-1 taking patients. No differences in rate of infection were found for any of the procedure types. Additional prospective trial research is needed to fully elucidate the potential impact of GLP-1 agonists on bony healing and postoperative outcomes.</p></sec><sec sec-type="supplementary-material" id="section10-10711007251328370"><title>Supplemental Material</title><supplementary-material id="suppl1-10711007251328370" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-pdf-1-fai-10.1177_10711007251328370 &#8211; Supplemental material for GLP-1 Agonists&#8217; Effect on Infection and Union after Tibiotalar Fusion, Subtalar Fusion, Triple Arthrodesis</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-pdf-1-fai-10.1177_10711007251328370.pdf" position="float" orientation="portrait"/><p>Supplemental material, sj-pdf-1-fai-10.1177_10711007251328370 for GLP-1 Agonists&#8217; Effect on Infection and Union after Tibiotalar Fusion, Subtalar Fusion, Triple Arthrodesis by Michael F. Levidy, Sohrab Vatsia, Scott Tucker, Nicholas Rowe, Ashlee Macdonald and Michael Aynardi in Foot &amp; Ankle International</p></supplementary-material></sec></body><back><fn-group><fn fn-type="other"><p><bold>Ethical Approval:</bold> Ethical approval was not sought for the present study because it uses a publicly available database of deidentified patient information</p></fn><fn fn-type="COI-statement"><p>The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Ashlee Macdonald, MD, reports general disclosures as AOFAS committee member. Michael Aynardi, MD, reports disclosures relevant to manuscript from Zimmer, Stryker, Arthrex, and general disclosures as AOFAS research chair. Disclosure forms for all authors are available online.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The author(s) received no financial support for the research, authorship, and/or publication of this article.</p></fn><fn fn-type="other"><p><bold>ORCID iDs:</bold> Michael F. Levidy, MD, <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1177_10711007251328370-img1.jpg"/>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0003-1591-8466" ext-link-type="uri">https://orcid.org/0000-0003-1591-8466</ext-link></p><p>Michael Aynardi, MD, <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1177_10711007251328370-img1.jpg"/>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0003-2944-4927" ext-link-type="uri">https://orcid.org/0000-0003-2944-4927</ext-link></p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-10711007251328370"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bendotti</surname><given-names>G</given-names></name><name name-style="western"><surname>Montefusco</surname><given-names>L</given-names></name><name name-style="western"><surname>Lunati</surname><given-names>ME</given-names></name></person-group>, <etal>et al</etal>. <article-title>The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists</article-title>. <source>Pharmacol Res</source>. <year>2022</year>;<volume>182</volume>:<fpage>106320</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.phrs.2022.106320</pub-id><pub-id pub-id-type="pmid">35738455</pub-id></mixed-citation></ref><ref id="bibr2-10711007251328370"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cardoso</surname><given-names>DV</given-names></name><name name-style="western"><surname>Veljkovic</surname><given-names>A.</given-names></name></person-group><article-title>General considerations about foot and ankle arthrodesis. Any way to improve our results?</article-title><source>Foot Ankle Clin</source>. <year>2022</year>;<volume>27</volume>(<issue>4</issue>):<fpage>701</fpage>-<lpage>722</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.fcl.2022.08.007</pub-id><pub-id pub-id-type="pmid">36368793</pub-id></mixed-citation></ref><ref id="bibr3-10711007251328370"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Q</given-names></name></person-group>, <etal>et al</etal>. <article-title>Glucagon-like peptide-1 attenuates diabetes-associated osteoporosis in ZDF rat, possibly through the RAGE pathway</article-title>. <source>BMC Musculoskelet Disord</source>. <year>2022</year>;<volume>23</volume>(<issue>1</issue>):<fpage>465</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12891-022-05396-5</pub-id><pub-id pub-id-type="pmid">35581617</pub-id><pub-id pub-id-type="pmcid">PMC9112483</pub-id></mixed-citation></ref><ref id="bibr4-10711007251328370"><label>4</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>L</given-names></name><name name-style="western"><surname>Costello</surname><given-names>RA.</given-names></name></person-group><part-title>Glucagon-like peptide-1 receptor agonists</part-title>. In: <source>StatPearls</source>. <publisher-name>StatPearls Publishing</publisher-name>; <year>2024</year>.<pub-id pub-id-type="pmid">31855395</pub-id></mixed-citation></ref><ref id="bibr5-10711007251328370"><label>5</label><mixed-citation publication-type="webpage"><collab>Food and Drug Administration</collab>. <article-title>Semaglutide [package insert]</article-title>. <year>2023</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://wwwaccessdatafdagoc/drugsatfda_docs/label/2024/215256s011blpdg" ext-link-type="uri">wwwaccessdatafdagoc/drugsatfda_docs/label/2024/215256s011blpdg</ext-link></mixed-citation></ref><ref id="bibr6-10711007251328370"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gariani</surname><given-names>K</given-names></name><name name-style="western"><surname>Putzu</surname><given-names>A.</given-names></name></person-group><article-title>Glucagon-like peptide-1 receptor agonists in the perioperative period: implications for the anaesthesiologist</article-title>. <source>Eur J Anaesthesiol</source>. <year>2024</year>;<volume>41</volume>(<issue>3</issue>):<fpage>245</fpage>-<lpage>246</lpage>. doi:<pub-id pub-id-type="doi">10.1097/EJA.0000000000001914</pub-id><pub-id pub-id-type="pmid">38298102</pub-id><pub-id pub-id-type="pmcid">PMC10842663</pub-id></mixed-citation></ref><ref id="bibr7-10711007251328370"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldberg</surname><given-names>EM</given-names></name><name name-style="western"><surname>Polachek</surname><given-names>WS</given-names></name><name name-style="western"><surname>Hynes</surname><given-names>K.</given-names></name></person-group><article-title>Ankle fractures in diabetic patients: a critical analysis</article-title>. <source>JBJS Rev</source>. <year>2023</year>;<volume>11</volume>(<issue>3</issue>):e22.00147. doi:<pub-id pub-id-type="doi">10.2106/jbjs.Rvw.22.00147</pub-id><pub-id pub-id-type="pmid">36927706</pub-id></mixed-citation></ref><ref id="bibr8-10711007251328370"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joshi</surname><given-names>GP</given-names></name><name name-style="western"><surname>Abdelmalak</surname><given-names>BB</given-names></name><name name-style="western"><surname>Weigel</surname><given-names>WA</given-names></name></person-group>, <etal>et al</etal>. <collab>American Society of Anesthesiologists (ASA) Task Force on Preoperative Fasting</collab>. <article-title>American Society of Anesthesiologists consensus-based guidance on preoperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists</article-title>. <source>American Society of Anesthesiologists Newsroom</source>. <year>2023</year>.</mixed-citation></ref><ref id="bibr9-10711007251328370"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Myers</surname><given-names>TG</given-names></name><name name-style="western"><surname>Lowery</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Frykberg</surname><given-names>RG</given-names></name><name name-style="western"><surname>Wukich</surname><given-names>DK.</given-names></name></person-group><article-title>Ankle and hindfoot fusions: comparison of outcomes in patients with and without diabetes</article-title>. <source>Foot Ankle Int</source>. <year>2012</year>;<volume>33</volume>(<issue>1</issue>):<fpage>20</fpage>-<lpage>28</lpage>. doi:<pub-id pub-id-type="doi">10.3113/fai.2012.0020</pub-id><pub-id pub-id-type="pmid">22381232</pub-id></mixed-citation></ref><ref id="bibr10-10711007251328370"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nauck</surname><given-names>MA</given-names></name><name name-style="western"><surname>Quast</surname><given-names>DR</given-names></name><name name-style="western"><surname>Wefers</surname><given-names>J</given-names></name><name name-style="western"><surname>Meier</surname><given-names>JJ.</given-names></name></person-group><article-title>GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art</article-title>. <source>Mol Metab</source>. <year>2021</year>;<volume>46</volume>:<fpage>101102</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.molmet.2020.101102</pub-id><pub-id pub-id-type="pmid">33068776</pub-id><pub-id pub-id-type="pmcid">PMC8085572</pub-id></mixed-citation></ref><ref id="bibr11-10711007251328370"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nuche-Berenguer</surname><given-names>B</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>P</given-names></name><name name-style="western"><surname>Esbrit</surname><given-names>P</given-names></name></person-group>, <etal>et al</etal>. <article-title>Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states</article-title>. <source>Calcif Tissue Int</source>. <year>2009</year>;<volume>84</volume>(<issue>6</issue>):<fpage>453</fpage>-<lpage>461</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00223-009-9220-3</pub-id><pub-id pub-id-type="pmid">19219381</pub-id></mixed-citation></ref><ref id="bibr12-10711007251328370"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oshba</surname><given-names>H</given-names></name><name name-style="western"><surname>Shaaban</surname><given-names>RHA</given-names></name><name name-style="western"><surname>Abdelrahman</surname><given-names>I</given-names></name><name name-style="western"><surname>Gougoulias</surname><given-names>N</given-names></name></person-group>. <article-title>Arthroscopic subtalar joint arthrodesis: Topical review</article-title>. <source>Foot Ankle Int</source>. <year>2021</year>;<volume>43</volume>(<issue>1</issue>):<fpage>131</fpage>-<lpage>145</lpage>. doi:10.1177/10711007211035397<pub-id pub-id-type="pmid">34549616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/10711007211035397</pub-id></mixed-citation></ref><ref id="bibr13-10711007251328370"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pereira</surname><given-names>M</given-names></name><name name-style="western"><surname>Jeyabalan</surname><given-names>J</given-names></name><name name-style="western"><surname>J&#248;rgensen</surname><given-names>CS</given-names></name></person-group>, <etal>et al</etal>. <article-title>Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice</article-title>. <source>Bone</source>. <year>2015</year>;<volume>81</volume>:<fpage>459</fpage>-<lpage>467</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bone.2015.08.006</pub-id><pub-id pub-id-type="pmid">26314515</pub-id></mixed-citation></ref><ref id="bibr14-10711007251328370"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sattar</surname><given-names>N</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MMY</given-names></name><name name-style="western"><surname>Kristensen</surname><given-names>SL</given-names></name></person-group>, <etal>et al</etal>. <article-title>Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2021</year>;<volume>9</volume>(<issue>10</issue>):<fpage>653</fpage>-<lpage>662</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s2213-8587(21)00203-5</pub-id><pub-id pub-id-type="pmid">34425083</pub-id></mixed-citation></ref><ref id="bibr15-10711007251328370"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terui</surname><given-names>S</given-names></name><name name-style="western"><surname>Akamatsu</surname><given-names>R</given-names></name><name name-style="western"><surname>Arai</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. <article-title>Immediate glucose-lowering effect after the first administration of dulaglutide: a retrospective, single-center, observational study</article-title>. <source>Diabetes Ther</source>. <year>2021</year>;<volume>12</volume>(<issue>11</issue>):<fpage>2873</fpage>-<lpage>2889</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13300-021-01147-2</pub-id><pub-id pub-id-type="pmid">34533697</pub-id><pub-id pub-id-type="pmcid">PMC8519979</pub-id></mixed-citation></ref><ref id="bibr16-10711007251328370"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tichy</surname><given-names>EM</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>JM</given-names></name><name name-style="western"><surname>Suda</surname><given-names>KJ</given-names></name></person-group>, <etal>et al</etal>. <article-title>National trends in prescription drug expenditures and projections for 2022</article-title>. <source>Am J Health Syst Pharm</source>. <year>2022</year>;<volume>79</volume>(<issue>14</issue>):<fpage>1158</fpage>-<lpage>1172</lpage>. doi:<pub-id pub-id-type="doi">10.1093/ajhp/zxac102</pub-id><pub-id pub-id-type="pmid">35385103</pub-id><pub-id pub-id-type="pmcid">PMC9383648</pub-id></mixed-citation></ref><ref id="bibr17-10711007251328370"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>LH</given-names></name><name name-style="western"><surname>Chrea</surname><given-names>B</given-names></name><name name-style="western"><surname>Meeker</surname><given-names>JE</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>JU</given-names></name><name name-style="western"><surname>Atwater</surname><given-names>LC.</given-names></name></person-group><article-title>Factors associated with nonunion and infection following ankle arthrodesis using a large claims database: who has elevated risk?</article-title><source>Foot Ankle Orthop</source>. <year>2022</year>;<volume>7</volume>(<issue>2</issue>):24730114221101617. doi:<pub-id pub-id-type="doi">10.1177/24730114221101617</pub-id><pub-id pub-id-type="pmcid">PMC9158424</pub-id><pub-id pub-id-type="pmid">35662901</pub-id></mixed-citation></ref><ref id="bibr18-10711007251328370"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yasui</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hannon</surname><given-names>CP</given-names></name><name name-style="western"><surname>Seow</surname><given-names>D</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>JG.</given-names></name></person-group><article-title>Ankle arthrodesis: a systematic approach and review of the literature</article-title>. <source>World J Orthop</source>. <year>2016</year>;<volume>7</volume>(<issue>11</issue>):<fpage>700</fpage>-<lpage>708</lpage>. doi:<pub-id pub-id-type="doi">10.5312/wjo.v7.i11.700</pub-id><pub-id pub-id-type="pmid">27900266</pub-id><pub-id pub-id-type="pmcid">PMC5112338</pub-id></mixed-citation></ref><ref id="bibr19-10711007251328370"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>C</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M</given-names></name><name name-style="western"><surname>Qu</surname><given-names>X.</given-names></name></person-group><article-title>The impact of glucagon-like peptide-1 on bone metabolism and its possible mechanisms</article-title>. <source>Front Endocrinol (Lausanne)</source>. <year>2017</year>;<volume>8</volume>:<fpage>98</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fendo.2017.00098</pub-id><pub-id pub-id-type="pmid">28515711</pub-id><pub-id pub-id-type="pmcid">PMC5413504</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>